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Mutational analysis of the CDKN2 gene in metastases from patients with
cutaneous malignant melanoma
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Summary We analysed 26 metastases from 25 patients with sporadic cutaneous malignant melanoma for
alterations in the CDKN2 gene by a combined polymerase chain reaction/single-strand conformation
polymorphism (PCR/SSCP)/nucleotide sequencing approach. Eleven alterations (one in exon 1, five in exon 2
and five in the 3' non-coding sequence of the exon 3 region) were concordantly and independently detected by
both SSCP and nucleotide sequence analysis. Two of the exon 2 changes and the five changes in the non-coding
exon 3 region are likely to represent natural polymorphism. Four (15%) of 26 metastases thus had CDKN2
mutations and belonged to 3 (12%) of 25 patients. Semi-quantitative PCR furthermore revealed no sign of
homozygous deletions of the CDKN2 exon 2 region. The results support an involvement of the CDKN2
product in the development of a subgroup of sporadic melanomas and encourage the search for alterations in
additional genes of the 9p21 region.
Keywords: CDKN2 mutation; human melanoma; metastases; polymerase chain reaction/single-strand
conformation polymorphism; sequence analysis
Allelic losses on chromosome 9p21 are very frequent in many
types of tumours and cell lines and thus suggest that 9p2l
may contain at least one tumour-suppressor locus involved in
the genesis of different human tumours, including malignant
melanoma. A putative tumour-suppressor gene CDKN2 maps
to 9p21 (Serrano et al., 1993; Kamb et al., 1994a; Nobori et
al., 1994) and encodes a protein, p16 ink4, identical to a
previously identified CDK4 inhibitory protein (Serrano et al.,
1993). CDKN2 contains three coding exons of 126, 307 and
11 bp (Serrano et al., 1993; Nobori et al., 1994).
Five to ten per cent of human malignant melanomas seem
to occur as a result of autosomal dominant inherited
predisposition (Greene et al., 1985) and at least two loci
linked with familial melanomas (on chromosome lp and 9p)
have been identified (Cannon-Albright et al., 1992; Goldstein
et al., 1993). Germline mutations in the CDKN2 gene have
now been detected in affected members from melanoma
families with 9p21 linkage (Hussussian et al., 1994; Kamb et
al., 1994b), suggesting that they indeed may represent
melanoma-predisposing alterations. The concept of cancer
heredity predicts the presence of a crucial primary alteration
in the germ line as being the only mechanistic difference
between the hereditary and the sporadic form of the disease.
Mutational alterations of CDKN2 detected in the germ line of
familial melanoma cases (Hussussian et al., 1994; Kamb et
al., 1994b) should therefore also occur as somatic alterations
in tumours of its sporadic counterparts.
The present report describes a successful mutational
analysis, carried out independently by polymerase chain
reaction (PCR) combined with single-strand conformation
polymorphism (SSCP) and by direct nucleotide sequence
analysis, of the CDKN2 gene in DNA from 26 melanoma
metastases of 25 patients with sporadic cutaneous malignant
melanoma.
Materials and methods
Tumour samples and DNA isolation
Fresh tumour tissues (26 metastases from lymph nodes and
skin) were obtained from 25 melanoma patients. The tumour
tissues were trimmed from surrounding non-tumour tissue
and dissected into small pieces and immediately frozen and
stored at -70°C. Representative parts of the frozen tissue
pieces were formalin fixed and 4 ,UM sections were hematox-
ylin stained. Patient and tissue data are summarised in Table
I. The frozen tissues were crushed to a fine powder under
liquid nitrogen and DNA extracted according to standard
procedures. The obtained DNA samples were stored as
precipitations under ethanol at -20°C.
PCR / SSCP analysis and nucleotide sequence analysis (SA)
The genomic regions containing exons 1 and 2 of CDKN2
were primarily amplified by PCR from genomic DNA using
the flanking primer sets 2F/1108R and 42F/551R (Kamb et
Table I Patient and tumour characteristics
Patient
no. Sex
AM Female
MA Female
SB Male
AA Female
LS Male
IN Male
JI Female
MP Male
Al Female
BT Male
LL Male
JA Male
HE Male
GK Male
GL Male
DO Male
TN Male
DJ Male
HW Male
HY Male
JIR Female
WN Male
RO Male
JH Female
EE Male
Anatomical site
ofprimary
tumour
Upper extremities
Lower extremities
Unknown primary
Lower extremities
Trunk
Lower extremities
Trunk
Trunk
Trunk
Trunk
Trunk
Trunk
Trunk
Trunk
Trunk
Lower extremities
Lower extremities
Lower extremities
Lower extremities
Trunk
Trunk
Lower extremities
Trunk
Lower extremities
Trunk
Location of
Histogenetic analysed
type metastases
NM
SSM
Unknown
Unclassified
NM
SSM
SSM
NM
NM
SSM
SSM
Unclassified
SSM
Unclassified
Unclassified
Unclassified
NM
Unclassified
SSM
SSM
NM
SSM
SSM
Unclassified
SSM
Skin
Lymph node
Lymph node
Lymph node
Lymph node
Lymph node
Skin
Skin
Lymph node
Skin
Skin
Skin
Lymph node
Skin
Skin
Skin
Lymph node
Lymph node
Skin
Lymph node
Lymph node
Lymph node
Skin
Lymph node
Skin
NM, nodular melanoma; SSM, superficial spreading melanoma.
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al., 1994a). For amplification of the third coding exon, a
346bp fragment was generated with the 5' primer
TTTTCTTTCTGCCCTCTGC and the 3' primer CCCA-
CATGAATGTGCGCTT. The following PCR conditions
were used. For exon 1, 4 min at 94°C, followed by 30
cycles consisting of 30 s at 94°C, 60 s at 63°C, 60 s at 72°C
and finally 7 min at 72°C. For exons 2 and 3, the same
amplification conditions were used, but with an annealing
temperature of 60°C. AmpliTaq DNA polymerase (Perkin
Elmer, Norwalk, CT, USA) was used in standard PCR buffer
at 1.5 mm magnesium chloride and in the presence of 5%
dimethyl sulphoxide (DMSO). The purity of the PCR
products was checked by electrophoresis on 4% NuSieve
agarose gels and ethidium bromide staining (PCR is covered
by US patents 4,683,195 and 4,683,202 owned by Hoffman-
La Roche).
The sequencing reactions were carried out by direct
sequencing of the PCR products using Pharmacia Biotech's
(Uppsala, Sweden) combs solid phase DNA sequencing
(Autoload kit) (Lagerkvist et al., 1994). One of the PCR
primers was biotinylated for the isolation of single-strand
DNA and FITC-modified sequencing primers were used for
the sequencing reactions. The electrophoretic separations
were performed on Pharmacia Biotech's ALF DNA
sequencer. Aliquots of 40 ,l of the PCR product were used
for capture on streptavidin-coated plastic combs. They were
incubated at room temperature for at least 30 min, then
transferred to a fresh plate for strand denaturation. The
combs were washed. FITC-modified sequencing primers (4
pmol) were used. After incubation at 55°C for 5 min, then at
room temperature for at least 10 min, the combs were
transferred to the sequencing-mixes containing T7 DNA Pol.
The combs were incubated at 37°C for 5 min and kept on ice
until loading. The electrophoretic gel was prewarmed at 45°C
and the well filled with formamide. The combs, specifically
designed to fit the gel, were inserted and incubated for 10 min
before being carefully removed and the run started. For exon
2, the sequencing was performed using two overlapping
pieces obtained by the internal primers p16-1B
(CACGCTGGTGGTGCTGCA) and p16-2B (CAGGTC-
1 2 3 4
CACGGGCAGACG) in combination with two M13 tail -
modified primers, 42FU (CCCAGTCACGACGTTGTAA-
AACGACGGCCAGTGGAAATTGGAAACTGGAAGC)
and 551RU (CCCAGTCACGACGTTGTAAAACGACGGC-
CAG7TCTGAGCTTTGGAAGCTCT) respectively. The se-
quencing was performed using the M13 Universal FITC
primer. The sequencing of the exon 3 region was carried out
using the primer PF3alR (F-TGATCTAAGTTTCCG-
GAGGT) or PF3a2R (F-CCTGTAGGACCTTCGGTGAC).
PCR amplifications of exon 1 for SSCP were carried out
as described above. PCR amplifications for SSCP of the exon
2 and exon 3 regions were carried out using the following
primer combinations: exon 2, AP167 ACACAAG-
CTTCCTTTCCGTC and AP168 TCAGATCATCAGTCCT-
CACC resulting in 392 bp fragments; and exon 3, 5' primer
TTTTCTTTCTGCCCTCTGC and 3' primer TTGTG-
GCCCTGTAGGACCTT, resulting in 108 bp fragments.
The amplified exon 1 and exon 2 fragments were cleaved
into two smaller pieces at single SmaI sites in order to obtain
smaller products for optimal SSCP runs (167 bp and 170 bp
for exon 1, 175 bp and 217 bp for exon 2). The PCR
products were 32p labelled by the use of either 32P end-
labelled primers or by incorporation of [a-32P] dCTP. The
SSCP runs were carried out as described by Mashiyama et al.
(1990). SSCP was performed both in the presence of 5%
glycerol at 18°C and in absence of glycerol at 5°C and, for
comparison, with both the intact and the cleaved exon 1 and
exon 2 fragments. The SSCP gels were dried and exposed to
Hyperfilm (Amersham, Buckinghamshire, UK) at -70°C for
1-3 days.
Semiquantitative PCR for detection of CDKN2 allelic losses
An internal standard, a 332 bp fragment of the ribosomal
protein HSS 26 gene (Vincent et al., 1993), was co-amplified
together with 509 bp of the p16 exon 2 region using the
primers HSS261 CCTATTCGCTGCACTAACTG / HSS262
CCAGAGAATAGCCTGTCTTC for ribosomal S26 and
42F / 551R for the CDKN2 exon 2 region (Kamb et al.,
1994a), in a multiplex PCR on genomic DNA. By
5 6 7
Figure 1 PCR/SSCP of CDKN2 exon 1, exon 2 and exon 3 regions. Patient samples with bandshifts: 1, patient HW, CDKN2 exon
1; 2, patient EE, CDKN2 exon 2; 3, patient MP, metastasis 1, CDKN2 exon 2; 4, patient MP, metastasis 2, CDKN2 exon 2; 5,
patient BT, CDKN2 exon 2; 6, patient JA, CDKN2 exon 2; 7, patient JI, CDKN2 exon 3.
Table II Results obtained by SSCP combined with nucleotide sequence analysis (SA)
p16 exon 1 p'6 exon 2 p16 exon 3
Patient sample SSCP SA SSCP SA SSCP SA
MP metastasis 1 No BS WT BS Arg 1 2 Glya CGT/GGT No BS WT
metastasis 2 No BS WT BS Arg 1l2 Gly CGT/GGT No BS WT
BT No BS WT BS Ala 148Thr GCG/ACG BS Nucleotide 499 G/C
JA No BS WT BS Ala 148Thr GCG/ACG BS Nucleotide 499 G/C
HW BS Insert of C, codon 4 No BS WT No BS WT
EE No BS WT BS His66stop CAC/TAG No BS WT
JI No BS WT No BS WT BS Nucleotide 499 G/C
HE No BS WT No BS WT BS Nucleotide 499 G/C
DJ No BS WT No BS WT BS Nucleotide 499 G/C
BS, bandshift; WT, wild-type. aAll numberings according to the sequence published by Serrano et al. (1993) but corrected for incompleteness at
the 5' end.CDKN2 mutations in human melanoma metastases
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amplifications of serial diluted genomic DNA from blood
samples from normal individuals and from genomic DNA of
tumours with hemizygote CDKN2 mutation we constructed
standard curves for analysis of the concentration-dependent
a.
co-amplification of the two gene regions. The multiplex PCR
reactions were carried out in standard PCR buffer in the
presence of 2 mM magnesium chloride and 5% DMSO (94°C,
30 s / 60°C, 30 s / 72°C, 30 s / 30 cycles). Co-amplification of
C
-A T A A T G C R- C G G A A G G T C C C
:14511' -146Asp 147Ala 148AIafThr 14:9Glu 160Gly 151 Pro
Figure 2 Examples of obtained sequencing results. (a) Wild-type sequence, codons 63 to 69 of CDKN2 exon 2. (b) Mutant sequence
(sample from patient EE) with stop codon in position 66. (c) Wild-type sequence, codons 145 -151. (d) polymorphic variant, codon
148 (sample from patient BT).CDKN2 mutations in human melanoma metastases
A Platz et a!
HSS26 and CDKN2 exon 2 was carried out at three dilution
steps for each of the 26 tumour DNA samples and the band
intensities obtained on ethidium bromide-stained agarose gels
were scanned with an Ultrascan XL Densitometer (Pharma-
cia Biotech) and compared with the corresponding part of the
standard curve in order to register a possible gene loss by
differential loss of the CDKN2 exon 2 specific band.
Results
The histopathological investigation of hematoxylin-eosin-
stained 4-,uM-thick sections, representative for the 26
dissected metastases, showed large and homogeneous
tumour cell populations. The majority of the sections
represented a minimum of 90% of tumour cells. PCR for
CDKN2 exon 1, exon 2 and exon 3 regions resulted in the
expected fragment sizes for all 26 samples. Gel electrophor-
esis on 4% NuSieve Agarose gels revealed no sign of small
deletions.
SSCP screening of the CDKN2 exon 1- and exon 2-
containing fragments was carried out, both in the presence
and absence of glycerol and revealed clear bandshifts for 6 of
the 25 metastatic samples. One bandshift in exon 1 and 5
bandshifts in exon 2 were detected (Figure 1). The shortening
of the analysed fragments containing exon 1 and exon 2 by
SmaI cleavage improved the recognised bandshifts. The wild-
type band was very weak or absent in three of the samples
with bandshifts in the exon 2-containing fragment, which
most likely indicates hemizygosity and also demonstrates that
normal cells are rare in the extracted tumour pieces. SSCP
screening of the exon 3-containing fragments, including the 3'
untranslated region, revealed in 5/26 (19%) of the samples an
identical bandshift, indicating the presence of a common
polymorphism (Figure 1). Xu et al. (1994) reported a C to G
polymorphism in the 3' untranslated region in 7/37 (19%) of
cases.
In agreement with Caldas et al. (1994) we found for all
sequenced samples a different nucleotide sequence 5' to the
ATG than the one published by Serrano et al. (1993). An
additional ATG codon at position -8 followed by seven
additional coding triplets was recognised. Furthermore codon
27 was found to be Gly instead of the originally published
Val (Serrano et al., 1993). All following nucleotide and codon
positions refer to the corrected sequence. Sequence changes
were recognised in the same samples that showed mobility
shifts in SSCP (Table II). The mutation in the exon 1 region
in the metastasis from patient HW turned out to be a single
C insertion at codon position 4 leading to a frameshift. Both
the mutated and the wild-type sequence were present. The
frameshift in the mutated sequence results in a nonsense
triplet TGA at codon position 14. The registered mutations in
exon 2 are (i) a missence mutation Argll2Gly (CGT/GGT)
found in two skin metastases from patient MP, and (ii) a
complex mutation converting His66CAC to nonsense TAG
by a C/T transition and a single-base frameshift deletion or
by deletion of codon 66 and its replacement by the
dinucleotide TA in the sample from patient EE (Figure 2b).
No wild-type sequence was detected in these three cases, thus
most probably pointing to loss of the wild-type allele. Two
additional mutations registered in metastases from patients
BT and JA were the same Alal48Thr (GCG/ACG) change,
earlier registered by others (Hussussian et al., 1994; Kamb et
al., 1994a), and represent a natural polymorphism (Figure
2d). Five out of 26 (19%) metastases had a G to C change in
base 499 of the 3' untranslated region of exon 3 and represent
most likely an additional common polymorphism (Xu et al.,
1994).
The semiquantitative multiplex PCR assay, measuring the
relative band intensities of the amplified fragment of the gene
for ribosomal protein HSS26 and of the CDKN2 exon 2
region on ethidium bromide-stained agarose gels showed no
obvious loss of the CDKN2-specific band in any of the 26
tested metastases.
Discussion
Homozygote deletions of CDKN2 have been recognised in
many cell lines derived from various human tumours and
subsets of cell lines retaining CDKN2 harboured structural
changes such as missense, nonsense and frameshift mutations
(Kamb et al., 1994a; Nobori et al., 1994). An increasing
number of mutational analyses of CDKN2 in non-cultured
primary and metastatic human tumours have been published
(Cairns et al., 1994; Mori et al., 1994; Okamoto et al., 1994;
Spruck et al., 1994; Zhang et al., 1994). Studies of somatic
CDKN2 alterations in human melanoma samples generated
conflicting results. Nucleotide sequence analysis of 30
surgically resected melanomas of cutaneous and uveal
origins could not detect any CDKN2 mutations (Ohta et
al., 1994). Five (15%) of 34 primary melanomas in a second
report in contrast had CDKN2 point mutations (Gruis et al.,
1995).
The present investigation reports the presence of CDKN2
mutations in metastases from 3 (12%) of 25 patients with
sporadic cutaneous malignant melanoma.
The combined SSCP/nucleotide sequence analysis ap-
proach as used in the present investigation convincingly
demonstrates that an SSCP prescreening of all three CDKN2
coding exon regions using a simple arrangement ofjust three
primer pairs and reduction of fragment sizes by single
restriction enzyme cleavage efficiently revealed the presence
of all mutations in the covered regions. Two of the three
types of registered mutations result in premature termination,
structural disruption and certainly loss of function of the
CDKN2 protein product p16.
The existence of homozygote CDKN2 losses among our
tumour samples seems to be unlikely, since no obvious loss of
the CDKN2-specific PCR signal was registered in any of the
samples and since the percentage of contaminating normal
cells was very small in the dissected tissue pieces. This does of
course not exclude the possibility that homozygous deletions
may be present in smaller subpopulations of the tumour cells,
which would need in situ hybridisation or in situ PCR
techniques for detection. The employed semiquantitative
PCR test, however, is an indicator for possible allelic losses
when used on DNA from early homogeneous cell popula-
tions and should certainly detect the presence of homozygous
deletions when present in the majority of a given cell
population.
The present finding of CDKN2 mutations in 12% of
patients with sporadic melanomas supports an involvement
of this gene in the development of a subgroup of sporadic
melanomas and also suggests that additional genes, other
than CDKN2, could be involved in melanoma development.
An additional gene adjacent to the CDKN2 gene has been
recognised at 9p2l that codes for the closely related protein
p15 (Hannon and Beach, 1994) and may be an alternative site
for alterations coupled to melanoma development. Muta-
tional analysis of the p15-coding sequences in the same
samples and in samples from primary tumour material is in
progress.
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